Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GROWTH-FOCUSED HEALTHCARE EXECUTIVE BRINGS 40 YEARS OF EXECUTIVE LEADERSHIP EXPERIENCE ACROSS MULTIPLE INDUSTRY SECTORS NEW YORK , SEPT. 25, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE APPOINTMENT OF ACCOMPLISHED HEALTHCARE EXECUTIVE JOHN R.

LUCID DIAGNOSTICS APPOINTS HEALTHCARE INDUSTRY VETERAN JOHN R. PALUMBO TO BOARD OF DIRECTORS

SCELFO TO STRENGTHEN AND SCALE LUCID'S MARKET ACCESS INFRASTRUCTURE AHEAD OF KEY UPCOMING REIMBURSEMENT MILESTONESINCLUDING MEDICARE COVERAGE FOR ESOGUARDAND TO ACCELERATE COMMERCIAL COVERAGE EXPANSION NEW YORK , SEPT. 16, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE APPOINTMENT OF DANIELLE SCELFO AS SENIOR VICE PRESIDENT, MARKET ACCESS & GOVERNMENT AFFAIRS, REPORTING TO THE CHIEF EXECUTIVE OFFICER.

LUCID DIAGNOSTICS APPOINTS DANIELLE SCELFO AS SENIOR VICE PRESIDENT, MARKET ACCESS & GOVERNMENT AFFAIRS

NEW YORK , SEPT. 11, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 28,750,000 SHARES OF ITS COMMON STOCK, INCLUDING 3,750,000 SHARES ISSUED PURSUANT TO THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES, AT A PUBLIC OFFERING PRICE OF $1.00 PER SHARE.

LUCID DIAGNOSTICS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK

NEW YORK , SEPT. 10, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 25,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $1.00 PER SHARE.

LUCID DIAGNOSTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

NEW YORK , SEPT. 9, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED ITS INTENTION TO OFFER SHARES OF COMMON STOCK THROUGH AN UNDERWRITTEN PUBLIC OFFERING.

LUCID DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

CONFERENCE CALL SCHEDULED FOR MONDAY, SEPTEMBER 8, AT 8:30 AM ET TO DISCUSS SEPTEMBER 4 MOLDX CONTRACTOR ADVISORY COMMITTEE (CAC) MEETING NEW YORK , SEPT. 5, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM)("PAVMED"), TODAY ANNOUNCED IT WILL HOST A CONFERENCE CALL ON MONDAY, SEPTEMBER 8, 2025, AT 8:30 A.M.

LUCID DIAGNOSTICS TO HOST INVESTOR CALL ON MONDAY, SEPTEMBER 8, 2025

FIRESIDE CHAT WITH CHAIRMAN & CEO LISHAN AKLOG, M.D., SCHEDULED FOR FRIDAY, SEPTEMBER 5, AT 8:35 AM EDT NEW YORK , AUG. 27, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM)("PAVMED"), TODAY ANNOUNCED LISHAN AKLOG, M.D.

LUCID DIAGNOSTICS TO PARTICIPATE IN THE CANTOR GLOBAL HEALTHCARE CONFERENCE 2025

NEWLY-FORMED PAVMED SUBSIDIARY TO LICENSE ENDOSCOPIC IMAGING TECHNOLOGY DESIGNED TO IDENTIFY AND FACILITATE ABLATIVE TREATMENT OF ESOPHAGEAL DYSPLASIA LUCID DIAGNOSTICS TO COLLABORATE WITH PAVMED AS A STRATEGIC AND EQUITY PARTNER ON THE TECHNOLOGY NEW YORK , AUG. 26, 2025 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY ANNOUNCED THAT IT HAS EXECUTED A NON-BINDING LETTER OF INTENT WITH DUKE UNIVERSITY TO LICENSE, THROUGH A NEWLY-FORMED SUBSIDIARY, DUKE'S TECHNOLOGY TO IDENTIFY AND FACILITATE TREATMENT OF ADVANCED ESOPHAGEAL PRECANCER (DYSPLASIA) DURING UPPER ENDOSCOPY. THIS TECHNOLOGYA MULTI-MODALITY PROBE COMBINING ANGLE-RESOLVED LOW COHERENCE INTERFEROMETRY (A/LCI) WITH OPTICAL COHERENCE TOMOGRAPHY (OCT)COULD ALLOW FOR A MORE EFFICIENT AND EFFECTIVE ALTERNATIVE TO TRADITIONAL BIOPSIES.

PAVMED SIGNS LETTER OF INTENT TO LICENSE GROUNDBREAKING ENDOSCOPIC ESOPHAGEAL IMAGING TECHNOLOGY

LUCID PROCESSED 2,756 ESOGUARD 2Q25 TESTS, RECOGNIZED REVENUE OF $1.2 MILLION,AND SECURED CAC MEETING ON MEDICARE LCD FOR ESOGUARD TO BE HELD ON SEPTEMBER4 VERIS HEALTH COMPLETED 2Q25 FINANCING, RELAUNCHED DEVELOPMENT OF IMPLANTABLEPHYSIOLOGICAL MONITOR, AND INITIATED INTEGRATION STEPS TO LAUNCH COMMERCIAL PHASE WITHOSU-THE JAMES CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, AUGUST 14, AT 8:30 AM EDT NEW YORK , AUG. 14, 2025 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND ITS SUBSIDIARIES, LUCID DIAGNOSTICS INC. (NASDAQ: LUCD) ("LUCID") AND VERIS HEALTH INC. ("VERIS"), AND REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025. CONFERENCE CALL AND WEBCAST THEWEBCASTWILL TAKE PLACE ON THURSDAY, AUGUST 14, 2025, AT 8:30 AM AND IS ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT PAVMED.COM.

PAVMED PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

PROCESSED 2,756 ESOGUARD TESTS AND RECOGNIZED 2Q25 REVENUE OF $1.2 MILLION, ENDING QUARTER WITH OVER $30 MILLION IN PROFORMA CASH AND EXTENDING RUNWAY WELL PAST UPCOMING REIMBURSEMENT MILESTONES MULTI-JURISDICTIONAL CONTRACTOR ADVISORY COMMITTEE (CAC) MEETING ON MEDICARE LOCAL COVERAGE DETERMINATION (LCD) FOR ESOGUARD TO BE HELD ON SEPTEMBER 4 CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, AUGUST 13, AT 8:30 AM EDT NEW YORK , AUG. 13, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM)("PAVMED"), TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025. CONFERENCE CALL AND WEBCAST THE WEBCAST WILL TAKE PLACE ON WEDNESDAY, AUGUST 13, 2025, AT 8:30 AM AND WILL BE ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT LUCIDDX.COM.

LUCID DIAGNOSTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

NEW YORK , AUG. 5, 2025 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: 10TH ANNUAL NEEDHAM VIRTUAL MEDTECH & DIAGNOSTICS 1X1 CONFERENCE 1X1 MEETINGS: AUGUST 11-12, 2025 LOCATION: VIRTUAL CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE FIRESIDE CHAT: AUGUST 13, 2025, AT 2:30 PM ET LOCATION: BOSTON, MA THE LIVE AND ARCHIVED WEBCAST OF THE CANACCORD GENUITY FIRESIDE CHAT CAN BE ACCESSED BY CLICKING HERE OR BY VISITING THE INVESTOR RELATIONS SECTION OF THE LUCID DIAGNOSTICS WEBSITE. A REPLAY OF THE WEBCAST WILL BE AVAILABLE ON THE WEBSITE FOR 30 DAYS FOLLOWING THE CONCLUSION OF THE LIVE BROADCAST.

Lucid Diagnostics Inc.

LUCD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Lucid Diagnostics Inc.

LUCD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LUCD